Key result
PKD3 is required for increasing the expression of NFATc4, Nkx2.5, and GATA4, acting as a pivotal mediator of the hypertrophic signaling cascade in pathological cardiac hypertrophy.
Why the study?
Does PKD3 mediate pathological cardiac hypertrophy through the up-regulation of cardiac transcription factors?
Population
In vitro and in vivo cardiac hypertrophic models
Comparison
Isoproterenol induction and PKD3 gene silencing vs Control models
Design
Preclinical
Authors
Loading...
PKD3 inhibition may warrant preclinical testing in hypertrophy; animal data leave translation to humans open.
Does PKD3 mediate pathological cardiac hypertrophy through the up-regulation of cardiac transcription factors?
PKD3 is identified as a pivotal mediator of the hypertrophic signaling cascade and a potential new drug target for pathological cardiac hypertrophy.
Li et al. (2011) studied Pathological cardiac hypertrophy. PKD3 gene silencing was evaluated on Expression of hypertrophic transcription factors (NFATc4, Nkx2.5, GATA4). PKD3 is required for increasing the expression of NFATc4, Nkx2.5, and GATA4, acting as a pivotal mediator of the hypertrophic signaling cascade in pathological cardiac hypertrophy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: